Resources
Filter by Topic
- Articles
Joseph Menzin, PhD, discusses the risks and rewards of fast-tracked COVID-19 studies.
- Press Releases
BHE, a leading healthcare analytics company, has announced the formation of its Strategic Advisory Board. The initial appointments include Peter Neumann, ScD, Director of the...
- Articles
Matthew Sussman, BHE's VP of Modeling & Strategy Services, discusses the use of remdesivir for COVID-19 patients and the risks and rewards of fast tracking...
- News & Events
Matthew Sussman, BHE's VP of Modeling & Strategy Services, discusses exploring strategies for facilitating access to the timely patient data and analysis needed for successful...
- News & Events
We formed a partnership with Premier Inc. to streamline data analytics and more quickly uncover strategies to improve patient care. Researchers and data scientists will...
- Press Releases
Boston Health Economics (BHE), a leading healthcare self-service analytics company, and Premier Healthcare Solutions, Inc. (Premier), a leading healthcare improvement company, are joining forces to...
- Articles
Healthcare IT Today article from Panalgo Founder and Executive Chairman, Joseph Menzin, PhD.
Faster Evidence, Fewer Bottlenecks: How IHD Is Redefining What’s Possible in Evidence Generation
As the demands on real-world data teams continue to grow, with more data sources, more stakeholders, and more pressure to deliver trusted evidence faster, the tools supporting that work need to evolve just as quickly.
Accelerating HEOR and Real-World Evidence: How IHD Helps Researchers Turn Evidence Into Impact
Health economics and outcomes research (HEOR), epidemiology, and real-world evidence (RWE) teams are under growing pressure to deliver meaningful insights faster than ever before. As healthcare stakeholders demand stronger evidence of clinical, economic, and humanistic value across the product life cycle, researchers need more than data—they need the right combination of technology, expertise, and fit-for-purpose evidence sources to turn research into impact.
How Pharma Leaders Are Rethinking Evidence Generation in the AI Era
Learn what organizations must do to balance speed, transparency, governance, and innovation in an increasingly data-driven and AI-reliant environment.
Where Treatment Slows in Metastatic NSCLC: A Real-World Data Analysis of Care Delays and Access Barriers
As regulators around the world grow more comfortable with real-world data (RWD) and AI-enabled evidence generation, pharma companies are rethinking how, and when, they build evidence.
Pharma’s New Regulatory Reality: Building Evidence for Launch and Beyond
As regulators around the world grow more comfortable with real-world data (RWD) and AI-enabled evidence generation, pharma companies are rethinking how, and when, they build evidence.
Smarter Data, Better Outcomes: How Real-World Data Is Transforming Evidence Generation Across the Product Lifecycle
As real-world data (RWD) becomes more central to healthcare decision making, evidence generation is playing an increasingly important role, from early identification to treatment optimization
IHD Analytics
Put reliable, rapid analytics in the hands of more people across your organization